668 related articles for article (PubMed ID: 12819936)
1. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule cyclin-dependent kinase modulators.
Senderowicz AM
Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
[TBL] [Abstract][Full Text] [Related]
3. Small molecule modulators of cyclin-dependent kinases for cancer therapy.
Senderowicz AM
Oncogene; 2000 Dec; 19(56):6600-6. PubMed ID: 11426645
[TBL] [Abstract][Full Text] [Related]
4. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Senderowicz AM
Leukemia; 2001 Jan; 15(1):1-9. PubMed ID: 11243375
[TBL] [Abstract][Full Text] [Related]
5. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Senderowicz AM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle modulators for the treatment of lung malignancies.
Senderowicz AM
Clin Lung Cancer; 2003 Nov; 5(3):158-68. PubMed ID: 14667271
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinases as targets for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Senderowicz AM
Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Shapiro GI
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
[TBL] [Abstract][Full Text] [Related]
14. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
[TBL] [Abstract][Full Text] [Related]
16. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
Perez RP; Lewis LD; Beelen AP; Olszanski AJ; Johnston N; Rhodes CH; Beaulieu B; Ernstoff MS; Eastman A
Clin Cancer Res; 2006 Dec; 12(23):7079-85. PubMed ID: 17145831
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
18. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Zhai S; Senderowicz AM; Sausville EA; Figg WD
Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Shapiro GI; Supko JG; Patterson A; Lynch C; Lucca J; Zacarola PF; Muzikansky A; Wright JJ; Lynch TJ; Rollins BJ
Clin Cancer Res; 2001 Jun; 7(6):1590-9. PubMed ID: 11410495
[TBL] [Abstract][Full Text] [Related]
20. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]